The decisions made at the Greater Manchester Medicines Management Group (GMMMG) and Clinical Effectiveness and Governance Committee (CEG) at their meetings in December 2025 have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary
- Betula verrucosa for allergic rhinitis or conjunctivitis – green (specialist initiation)
- Guselkumab for ulcerative colitis and Crohn’s disease – red
- Relugolix / estradiol / norethisterone and linzagolix for uterine fibroids and endometriosis – green (specialist initiation)
- Idebenone for Leber’s hereditary optic neuropathy – red
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
The following are also available:
- Melatonin for children and adolescents shared care protocol – https://gmmmg.nhs.uk/shared-care/gmmmg-approved-shared-care-protocols/
For full details of new and updated pathways, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.